Evidence map›Paper›PMID 39263383›Full record

ArticleCritical care explorations2024

Clinical Phenotyping for Prognosis and Immunotherapy Guidance in Bacterial Sepsis and COVID-19.

Eleni Karakike, Simeon Metallidis, Garyfallia Poulakou, Maria Kosmidou, Nikolaos K Gatselis, Vasileios Petrakis, Nikoletta Rovina, Eleni Gkeka, Styliani Sympardi, Ilias Papanikolaou and 16 more

Abstract read
In one paragraph

Article in Critical care explorations, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Eleni Karakike4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Simeon Metallidis1st Department of Internal Medicine, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece.
Garyfallia Poulakou3rd Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Maria Kosmidou1st Department of Internal Medicine, University General Hospital of Ioannina, Ioannina, Greece.
Nikolaos K GatselisDepartment of Internal Medicine, Larissa University General Hospital, University of Thessaly, Larissa, Greece.
Vasileios Petrakis2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece.
Nikoletta Rovina1st Department of Pulmonary Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Eleni GkekaIntensive Care Unit, AHEPA University General Hospital of Thessaloniki, Thessaloniki, Greece.
Styliani Sympardi1st Department of Internal Medicine, Elefsis General Hospital Thriassio, Elefsis, Greece.
Ilias PapanikolaouDepartment of Pulmonary Medicine, Kerkyra General Hospital, Corfu, Greece.
Ioannis KoutsodimitropoulosIntensive Care Unit of Latseion Burn Center, Elefsis General Hospital Thriassio, Elefsis, Greece.
Vasiliki Tzavara1st Department of Internal Medicine, "Korgialeneio-Benakeio" Athens General Hospital, Athens, Greece.
Georgios Adamis1st Department of Internal Medicine, "G.Gennimatas" Athens General Hospital, Athens, Greece.
Konstantinos Tsiakos3rd Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Vasilios KoulourasDepartment of Critical Care Medicine, University General Hospital of Ioannina, Ioannina, Greece.
Eleni MouloudiIntensive Care Unit, "Ippokrateion" General Hospital of Thessaloniki, Thessaloniki, Greece.
Eleni AntoniadouIntensive Care Unit, "G.Gennimatas" General Hospital of Thessaloniki, Thessaloniki, Greece.
Gykeria VlachogianniIntensive Care Unit, "Aghios Dimitrios" General Hospital of Thessaloniki, Thessaloniki, Greece.
Souzana AnisoglouIntensive Care Unit, "Theageneion" General Hospital of Thessaloniki, Thessaloniki, Greece.
Nikolaos MarkouIntensive Care Unit of Latseion Burn Center, Elefsis General Hospital Thriassio, Elefsis, Greece.
Antonia Koutsoukou1st Department of Pulmonary Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Periklis Panagopoulos2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece.
Haralampos Milionis1st Department of Internal Medicine, University General Hospital of Ioannina, Ioannina, Greece.
George N DalekosDepartment of Internal Medicine, Larissa University General Hospital, University of Thessaly, Larissa, Greece.
Miltiades KyprianouHellenic Institute for the Study of Sepsis, Athens, Greece.
Evangelos J Giamarellos-Bourboulis4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesIt is suggested that sepsis may be classified into four clinical phenotypes, using an algorithm employing 29 admission parameters. We applied a simplified phenotyping algorithm among patients with bacterial sepsis and severe COVID-19 and assessed characteristics and outcomes of the derived phenotypes.

designRetrospective analysis of data from prospective clinical studies.

settingGreek ICUs and Internal Medicine departments. PATIENTS AND

interventionsWe analyzed 1498 patients, 620 with bacterial sepsis and 878 with severe COVID-19. We implemented a six-parameter algorithm (creatinine, lactate, aspartate transaminase, bilirubin, C-reactive protein, and international normalized ratio) to classify patients with bacterial sepsis intro previously defined phenotypes. Patients with severe COVID-19, included in two open-label immunotherapy trials were subsequently classified. Heterogeneity of treatment effect of anakinra was assessed. The primary outcome was 28-day mortality. MEASUREMENTS AND MAIN

resultsThe algorithm validated the presence of the four phenotypes across the cohort of bacterial sepsis and the individual studies included in this cohort. Phenotype α represented younger patients with low risk of death, β was associated with high comorbidity burden, and δ with the highest mortality. Phenotype assignment was independently associated with outcome, even after adjustment for Charlson Comorbidity Index. Phenotype distribution and outcomes in severe COVID-19 followed a similar pattern.

conclusionsA simplified algorithm successfully identified previously derived phenotypes of bacterial sepsis, which were predictive of outcome. This classification may apply to patients with severe COVID-19 with prognostic implications.

Indexed as

AlgorithmsCOVID-19ImmunotherapyPhenotypeSepsisAgedBacterial InfectionsFemaleGreeceHumansInterleukin 1 Receptor Antagonist ProteinMaleMiddle AgedPrognosisRetrospective StudiesSARS-CoV-2Interleukin 1 Receptor Antagonist ProteinCOVID-19immunotherapymortalityphenotypessepsis

Identifiers

PMID39263383
PMCPMC11390041

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.